← All trials
NCT03760588
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2019
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oslo Metropolitan UniversityLead sponsor
- University of StavangerCollaborator
- University of OsloCollaborator
- Norwegian Cancer SocietyCollaborator
- University of OsloCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Oslo Metropolitan UniversityCollaborator
- Oslo Metropolitan UniversityOverall official - principal investigator
- Oslo Metropolitan UniversitySponsor investigator
- University Hospital of North NorwayCollaborator
- NovartisCollaborator
- Oslo Metropolitan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.